Study Finds Ayahuasca Affects Epigenetic Gene Expression
In this Gaia News special investigation, we take a look at groundbreaking new research being done on ayahuasca, an ancient psychedelic plant medicine showing great promise in addressing the most difficult to treat mental health conditions, and may even change our DNA.
Dr. Simon Ruffle is a psychiatrist and researcher who led this study conducted in the Peruvian Amazon.
“Ayahuasca is a psychedelic brew that is used in the Amazon rainforest. It’s been used for at least hundreds of years and there’s some evidence that suggests that it may have been used for thousands of years,” Ruffell said.
“It’s used for a wide variety of purposes and normally by indigenous tribes. It’s used most commonly, now, for healing. And there’s been a lot of interest from people from the West going to the Amazon rainforest in order to drink ayahuasca. And also ayahuasca is spreading all over the world and now can be found on pretty much every continent.”
Watch Part 1:
In part two we look at how researchers found a statistically significant change in the expression of the SIGMAR-1 gene which is thought to be involved with how traumatic memories are recalled.
Watch Part 2:
About the Author
Study Shows Microdosing Psilocybin Boosts Mood, Mental Health
A new study provides the most compelling evidence to date on the impressive mental health benefits of microdosing psilocybin.
While there has been an ever-increasing number of studies showing the efficacy of treatment of mental health disorders with psychedelics, there has been relatively little research on the practice of microdosing.
Microdosing, or repeatedly taking small, barely perceptible amounts of psychedelics, has been exponentially increasing in popularity, with a wide range of people reporting a multitude of improvements to their psychological wellbeing.
The latest scientific study to look at the effects of microdosing was conducted by researchers at the University of British Columbia, as well as other leaders in the fields of psychology and mycology. The study followed 953 people who used small, repeated doses of psilocybin for about 30 days, as well as a control group who did not microdose.
While the exact dosages of psylocibin that participants self-administered varied somewhat, they were all low enough to not impact daily functioning.
Over a one-month period, participants took these psylocibin microdoses three to five times per week and were asked to complete a number of assessments through a smartphone app that tracked their mental health symptoms, mood, and measures of cognition. The findings definitively showed that the microdosing participants demonstrated greater improvements in mood and mental health than those in the non-microdosing control group.
